文献类型：期刊文献

中文题名：信号通路与糖尿病视网膜病变的关系及中医药干预研究进展

英文题名：Relationship Between Signaling Pathway and Diabetic Retinopathy and Intervention of Traditional Chinese Medicine:A Review

作者：刘素珍[1];杨浩东[1];张花治[1];孙金宁[1];刘晖[1]

第一作者：刘素珍

机构：[1]甘肃中医药大学,兰州730000

第一机构：甘肃中医药大学

年份：2023

卷号：29

期号：22

起止页码：265

中文期刊名：中国实验方剂学杂志

外文期刊名：Chinese Journal of Experimental Traditional Medical Formulae

收录：CSTPCD;;北大核心:【北大核心2020】；CSCD:【CSCD2023_2024】；

基金：甘肃省自然科学基金项目(21JR1RA260);甘肃省高等学校创新能力提升项目(2020A-082);甘肃省中医药科研课题项目(GZKP-2021-33);甘肃中医药大学中医学一级学科“岐黄英才”导师专项基金项目(ZYXKSD-202208)。

语种：中文

中文关键词：中医药;糖尿病视网膜病变;信号通路;研究进展

外文关键词：traditional Chinese medicine;diabetic retinopathy;signaling pathways;research progress

摘要：糖尿病视网膜病变(DR)是糖尿病最常见的慢性微血管并发症之一,具有较高的致盲率且发病年龄逐渐呈年轻化趋势,严重影响患者的身心健康及生活质量。该病是由糖尿病诱导的视网膜损伤,是以眼底出血、硬性渗出、微血管瘤、棉絮斑、新生血管生成等为主要表现的一类眼底病变,中医将其归于“消渴内障”等病证范畴。目前,现代医学尚无有效阻止该病进展的方法,因此选择一种合理有效的干预措施来防治DR显得尤为重要。研究证实,中医药在治疗DR方面具有独特的优势,可利用其多生物活性成分、多靶标、多路径等优势,对DR的发展过程进行多方位干预。笔者通过对中药单体及复方干预DR进展相关文献进行查阅,重点对中药单体及复方调控磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)、核转录因子-κB(NF-κB)、p38丝裂原活化蛋白激酶(p38 MAPK)、核转录因子E2相关因子2(Nrf2)/血红素氧合酶-1(HO-1)、Hippo、晚期糖基化终末产物(AGEs)/糖基化终末产物受体(RAGE)、Akt/糖原合成酶激酶-3β(GSK-3β)等多条信号通路治疗DR的相关研究成果进行综述,旨在为临床防治DR提供更多思路和方向。
Diabetic retinopathy(DR)is one of the most common chronic microvascular complications of diabetes mellitus.It has a high rate of blindness,and the age of onset is gradually getting younger,which seriously affects the physical and mental health and quality of life of patients.The disease is retinal damage induced by diabetes mellitus,which is a kind of fundus disease with the main manifestations of fundus hemorrhage,hard exudation,microhemangioma,cotton-wool spots,neovascularization,etc.In traditional Chinese medicine(TCM),it is classified into the category of"diabetic cataracts"and other diseases.At present,there is no effective method to prevent the progress of the disease in modern medicine,so it is particularly important to choose a reasonable and effective intervention to prevent and treat DR.Studies have confirmed that TCM has unique advantages in the treatment of DR.It can use its advantages of multiple bioactive components,multiple targets,and multiple pathways to intervene in the development process of DR from various aspects.By searching for the relevant literature on the progress of the intervention of DR with TCM monomers and compounds,this paper mainly reviews the relevant research results of the treatment of DR with multiple signaling pathways such as phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt),nuclear factor kappa-B(NF-κB),p38 mitogen-activated protein kinase(p38 MAPK),nuclear factor erythroid 2-related factor(Nrf2)/hemeoxygenase-1(HO-1),Hippo,advanced glycation end products(AGEs)/receptor for advanced glycation end products(RAGE),and Akt/glycogen synthase kinase-3β(GSK-3β),so as to provide more ideas and directions for the clinical prevention and treatment of DR.